| Immune checkpoint association |
| nivolumab plus ipilimumab | relatlimab plus nivolumab |
| mML - 1st line (L1) | | |
| mML - L1 - all population 7 | | |
| mML - L1 - BRAF mutant 2 | | |
| mML - L1 - BRAF wild 3 | | |
Comparator:
vs ipilimumab alone; vs nivolumab alone;
Risk of bias:
low;
some concerns;
high;
NA;